CliffBio
small molecule

AKYNZEO

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

Loss of exclusivityJune 2037latest FDA-listed patent expiry
CompanyHELSINN HEALTHCARE SA

Drug detail

Brand nameAKYNZEO
Active ingredientFOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE
StrengthEQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
10624911June 2037product
11529362June 2037product
12208109June 2037product
11312698May 2032substance, product
8426450May 2032substance, product
10717721May 2032substance
8895586May 2032use U-2301
9403772May 2032substance
9908907May 2032substance, product
10208073May 2032use U-2301
10828297December 2030use U-2301
9186357November 2030use U-2301

More from HELSINN HEALTHCARE SA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AKYNZEO patent cliff — loss of exclusivity June 2037 | CliffBio